The value of the live cell imaging market stood at USD 2,829.9 million in 2023, and this number is projected to reach USD 5,634.3 million by 2030, advancing at a CAGR of 10.4% during the projection period.
Live cell studies are an effective way of understanding the dynamics of cellular processes and events. For this reason, there has been an increasing adoption of live cell imaging technology in a wide range of fields such as drug discovery, healthcare research, stem cell biology, and cellular environment studies.
Furthermore, the growing number of chronic diseases, in particular cancer, and the rapid adoption of high-content HHCS screening techniques for drug discovery are contributing to market growth.
Biotechnology and pharmaceutical businesses have accepted numerous progressive methodologies to overcome the challenges of saving time and money during medication safety and toxicity monitoring, one of which is HCS through cell-based assays. The technique is quicker and more precise and provides an advanced success rate than old-style approaches.
In 2023, the North American region led the worldwide industry, with a share of 50%. The supremacy of the continent can be credited to the growing occurrence of severe and chronic illnesses and the rising research and development spending of biotech and pharma businesses. During the projection period, the consumables category is projected to advance with a CAGR of 10.6%.
The development is because of the increasing R&D in the biotechnology market, which generates a huge need for kits, reagents, and other consumables for lasting and fast live cell imaging and analysis.
Such reagents and consumables help in getting meaningful data, as they reserve cell health long sufficient for experts to extract whatever insights they require. Moreover, advanced reagents aid in generating rich data from a single cell, using fluorescent reagent blends in cell cultures. Thus, since consumables need to be obtained recurrently, the category will endure to advance.
